Use of Pre-Clinical In Vitro and In Vivo Pharmacokinetics for the Selection of a Potent Hepatitis C Virus Protease Inhibitor, Boceprevir, for Clinical Development

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|6|4|312-318

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.6, Iss.4, 2009-06, pp. : 312-318

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of P-Glycoprotein in the Pharmacokinetics and Tissue Distribution of a Hepatitis C Virus Protease Inhibitor

By  

Drug Metabolism Letters, Vol. 3, Iss. 4, 2009-12 ,pp. : 290-295

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical and Preclinical Pharmacokinetics of Raltitrexed

By Clarke S.J.  

Clinical Pharmacokinetics, Vol. 39, Iss. 6, 2000-12 ,pp. : 429-443

Adis International

Access to resources Recommend Favorite

Clinical virology of hepatitis C virus

By Chevaliez Stéphane   Pawlotsky Jean-Michel  

Future Virology, Vol. 1, Iss. 5, 2006-09 ,pp. : 649-657

Future Medicine

Access to resources Recommend Favorite

The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus

By Shankar Hari   Bichoupan Kian   Dieterich Douglas T  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 12, 2013-12 ,pp. : 1647-1657

Informa Healthcare

Access to resources Recommend Favorite

Discovery and Development of VX-950, a Novel, Covalent, and Reversible Inhibitor of Hepatitis C Virus NS3.4A Serine Protease

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 6, Iss. 1, 2006-03 ,pp. : 3-16

Bentham Science Publishers

Access to resources Recommend Favorite